Please assess the completion status of the following clinical trial:

Trial Title: Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders.~* Age 18 years and 70 years.~* Postoperative Karnofsky Performance Status \>=70.~* Diagnosis of recurrent GBM (World Health Organization \[WHO\] grade IV astrocytoma).~* Diagnosis confirmed by the reference histopathology.~* Total or subtotal resection of tumor mass, confirmed by assessment of the neurosurgeon and by postoperative radiological assessment.~* Amount of non-necrotic tissue for lysate preparation and DC loading \>= 1 gr, stored at -80°C.~* Corticosteroids daily dose \<= 4 mg during the 2 days prior to leukapheresis.~* Life expectancy \> 3 months.~* Signed informed consent.~Exclusion Criteria:~* Pregnancy.~* Participation in other clinical trials with experimental drugs simultaneously or within 1 month before this trial entry.~* Presence of acute infection requiring active treatment.~* Mandatory treatment with corticosteroids or salicylates in anti-inflammatory dose.~* Presence of sub-ependymal diffusion of the tumor.~* Haematology: leukocytes \< 3,000/μl, lymphocytes \< 500/μl, neutrophils \< 1,000/μl, hemoglobin \<9 g/100 ml, thrombocytes \< 100,000/μl 2 days prior to leukapheresis.~* Documented immune deficiency.~* Documented autoimmune disease.~* Positive serology for HIV or hepatitis B or C.~* Allergies to any component of the DC vaccine.~* Known intolerance to TMZ.~* Other active malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Immunotherapy (Type: EXPERIMENTAL): Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).